Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli

@article{Zhanel2019CefiderocolAS,
  title={Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli},
  author={George G. Zhanel and Alyssa R. Golden and Sheryl A. Zelenitsky and Karyn Wiebe and Courtney K. Lawrence and Heather J. Adam and Temilolu Idowu and Ronald Domalaon and Frank Schweizer and Michael A. Zhanel and Philippe R.S. Lagac{\'e}-Wiens and Andrew Walkty and Ayman Noreddin and Joseph P Lynch Iii and James A. Karlowsky},
  journal={Drugs},
  year={2019},
  volume={79},
  pages={271-289}
}
Cefiderocol is an injectable siderophore cephalosporin discovered and being developed by Shionogi & Co., Ltd., Japan. As with other β-lactam antibiotics, the principal antibacterial/bactericidal activity of cefiderocol occurs by inhibition of Gram-negative bacterial cell wall synthesis by binding to penicillin binding proteins; however, it is unique in that it enters the bacterial periplasmic space as a result of its siderophore-like property and has enhanced stability to β-lactamases. The… 

Figures and Tables from this paper

Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
  • Takafumi Sato, K. Yamawaki
  • Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2019
TLDR
Cefiderocol has demonstrated promising in vitro antibacterial and bactericidal activity, which correlates with its in vivo efficacy in several animal models, as well as some of the key microbiological and in vivo findings on cefIDERocol from recently conducted investigations.
Burkholderia pseudomallei Clinical Isolates Are Highly Susceptible In Vitro to Cefiderocol, a Siderophore Cephalosporin
TLDR
The in vitro activity of cefiderocol was found to be highly active in vitro against B. pseudomallei primary clinical isolates and shows great potential for the treatment of melioidosis in countries of endemicity and should be explored further.
Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
TLDR
The purpose of this article is to review existing data on the mechanism of action, microbiology, pharmacokinetics, pharmacodynamics, efficacy, and safety of cefiderocol to assist clinicians in determining its place in therapy.
Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
TLDR
Clinical outcome data are required to assess the effectiveness of cefiderocol for treatment of other Acinetobacter species (non-baumannii complex) and Stenotrophomonas maltophilia at this time, and antimicrobial susceptibility testing of these organisms should be limited to research use in the scenario of limited treatment options.
Burkholderia pseudomallei clinical isolates are highly susceptible in vitro to cefiderocol, a novel siderophore cephalosporin
TLDR
Cefiderocol was found to be highly active in vitro against B. pseudomallei primary clinical isolates and shows great potential for the treatment of melioidosis in endemic countries and should be explored further.
New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae
TLDR
It is shown that the presence of the New Delhi metallo-β-lactamase (NDM) facilitates the emergence of resistance via nonsynonymous mutations of the CirA catecholate siderophore receptor in cefiderocol-resistant mutants.
In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against Acinetobacter baumannii Strains Recovered from Clinical Samples
TLDR
Cefiderocol showed in vitro antimicrobial activity against both carbapenem-susceptible and non-sUSceptible A. baumannii strains, although some OXA-23-like producers were resistant.
Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug‐Resistant Gram‐Negative Pathogens
TLDR
The unique features and enhanced activity of CFDC suggest that it is likely to serve as a viable therapeutic option in the treatment of MDR Gram‐negative infections.
A Novel Antibiotic Agent, Cefiderocol, for Multidrug-Resistant Gram-Negative Bacteria
TLDR
It is concluded that cefiderocol is a potent treatment option for prospective bacterial infections because of its siderophore-like properties and modification at the C-3 and C-7 side-chains produces powerful antibacterial properties against MDR gram-negative bacteria.
Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii
TLDR
Interestingly, it was showed that combination of FDC with avibactam showed an excellent activity against all multidrug-isolates isolates co-producing OXA-23 and PER-type ß-lactamases.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 69 REFERENCES
Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
TLDR
Time-kill experiments and animal infection models have demonstrated that the pharmacokinetic–pharmacodynamic index that is best correlated with ceftolozane’s in vivo efficacy is the percentage of time in which free plasma drug concentrations exceed the minimum inhibitory concentration of a given pathogen, as expected of β-lactams.
In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria
ABSTRACT Cefiderocol (CFDC; S-649266), a novel parenteral siderophore cephalosporin conjugated with a catechol moiety, has a characteristic antibacterial spectrum with a potent activity against a
Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens
TLDR
Compared to the other drugs tested, cefiderocol was more active, with the exception of colistin and tigecycline showing equivalent activity against certain subgroups of bacteria.
1351. In vitro Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, Against Enterobacteriaceae With Defined Extended-Spectrum Β-Lactamases and Carbapenemases
TLDR
Compared with isolates without ESBLs and carbapenemases, cefiderocol shows higher MICs against isolates withESBLs, including TEM, SHV, and CTX-M and carbamases including KPC, NDM, and OXA, which is dependent on the pharmacokinetic and pharmacodynamic properties of cefIDERocol.
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
TLDR
It is concluded that cefiderocol demonstrated potent in vitro activity against a 2014–2016, worldwide collection of clinical isolates of carbapenem-nonsusceptible Enterobacteriaceae, MDR A. baumannii,MDR P. aeruginosa, S. maltophilia, and B. cepacia.
ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases
TLDR
The activity of cefiderocol against characterized carbapenem-resistant Acinetobacter baumannii complex, Stenotrophomonas maltophilia, Pseudomonas aeruginosa, and Enterobacteriaceae strains was determined by microdilution in iron-depleted Mueller-Hinton broth.
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)
TLDR
It is concluded that cefiderocol demonstrated potent in vitro activity against a recent collection of clinical isolates of commonly encountered Gram-negative bacilli, including carbapenem-nonsusceptible isolates.
In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains
TLDR
This is the first report to demonstrate that S-649266, a novel siderophore cephalosporin, has significant antimicrobial activity against Enterobacteriaceae, including strains that produce carbapenemases such as KPC and NDM-1.
Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals
TLDR
Cefiderocol exhibited greater antimicrobial activity in vitro against carbapenem-resistant Gram-negative bacteria than comparator antibiotics.
Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
TLDR
Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus β-lactamase-producing Gram-negative bacilli that are not inhibited by ceftAZidime alone.
...
1
2
3
4
5
...